2023 World Conference on Lung Cancer (Posters)-EP12.01. Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort

EP12.01. Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort - PDF(Slides)

Back to course

Pdf Summary

A recent study conducted by the Mayo Clinic examined the occurrence and effects of skin toxicity in patients with stage-IV non-small cell lung cancer (NSCLC) who were treated with targeted and immunotherapies over a 14-year period. The study aimed to provide additional insights into the profile and predictive value of dermatologic toxicities in these patients.<br /><br />The researchers analyzed data from 596 newly diagnosed NSCLC patients who received targeted and immunotherapies without concurrent chemoradiation at the Mayo Clinic from 2006 to 2019. They compared three toxicity subgroups: skin, other, and none. Survival analyses were conducted using Kaplan-Meier curves and Cox Proportional Hazard models.<br /><br />The study found that skin toxicities were more prevalent in never-smokers and patients with epidermal growth factor receptor (EGFR) mutations compared to smokers and non-EGFR patients. Specifically, smoker women with EGFR mutations had a lower incidence of skin toxicity compared to never-smoker women and smoker men.<br /><br />Furthermore, the study revealed that skin toxicity associated with targeted drugs was linked to better response to therapy and longer survival, particularly with erlotinib. The most common drugs related to skin toxicities were erlotinib, afatinib, and osimertinib, which caused adverse effects such as rash, pruritus, xerosis, erythema, mucositis, and paronychia.<br /><br />In terms of survival analysis, no significant differences were observed between the three toxicity groups (skin, other, and none) in the overall study population or among patients specifically treated with EGFR inhibitors. However, among patients treated with erlotinib, those with skin toxicity had better survival.<br /><br />Overall, this study provides valuable insights into the occurrence and effects of skin toxicities in patients with stage-IV NSCLC receiving targeted and immunotherapies. The findings suggest that skin toxicity may serve as a predictor of drug response and survival outcomes in these patients.

Asset Subtitle

Ping Yang

Meta Tag

Speaker Ping Yang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Mayo Clinic

skin toxicity

non-small cell lung cancer

NSCLC

targeted therapies

immunotherapies

dermatologic toxicities

survival analysis

EGFR mutations

drug response